Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mary Cannon is active.

Publication


Featured researches published by Mary Cannon.


Schizophrenia Research | 1996

Autoimmune diseases in the pedigrees of schizophrenic and control subjects

Padraig Wright; Pak Sham; Catherine Gilvarry; Peter B. Jones; Mary Cannon; Tonmoy Sharma; Robin M. Murray

Autoimmune diseases aggregate in individuals and within pedigrees, and it has been postulated that autoimmune mechanisms may account for a proportion of schizophrenia. Structured questionnaires were used to interview the mothers of 121 DSM-III-R schizophrenic patients and the mothers of 116 controls in order to determine the prevalence of schizophrenia and of autoimmune diseases in their pedigrees. Patients with a schizophrenic first degree relative were significantly more likely to also have a parent or sibling with an autoimmune disease (60% vs. 20%, OR = 6.1, 95% CI = 2.3-6.5, p = 0.0003). A significant excess of insulin dependent diabetes mellitus (IDDM) was present in the parents and siblings of schizophrenic patients (OR = 9.65, 95% CI = 1.3-429.2, p = 0.009). These findings suggest that autoimmune mechanisms may play a role in the aetiology of schizophrenia, particularly familial schizophrenia. Associations have been established between autoimmune diseases and the HLA encoding genes of the major histocompatibility complex on chromosome six, and it may be that some of the genetic liability to schizophrenia involves these genes.


The American Journal of Gastroenterology | 2018

Non-Invasive Markers (ALBI and APRI) Predict Pregnancy Outcomes in Women With Chronic Liver Disease

Enoka S. Gonsalkorala; Mary Cannon; Tiong Yeng Lim; Leonie Penna; Catherine Willliamson; Michael A. Heneghan

objectives: Rates of pregnancy in women with cirrhosis are increasing. Risk of hepatic decompensation during pregnancy, therefore, merits tailored obstetric and hepatology care. Prognostic markers that determine pregnancy outcomes are lacking. METHODS: Medical records of women who attended hepatology clinic at King’s College Hospital with chronic liver disease (CLD) who became pregnant from 1983 to 2017 were reviewed. Information on demographics, clinical history, serology, and outcome of pregnancy was collected. RESULTS: In all, 165 pregnancies occurred in 100 women with CLD including 80 pregnancies in 48 women with cirrhosis. Median age of conception in cirrhotic and non-cirrhotic women were 26 years (16–44) and 28 years (16–51) respectively (p = 0.015). Whilst women with cirrhosis had similar live birth rate to non-cirrhotic women (75 vs. 85% p = 0.119), they were significantly less likely to proceed beyond 37 weeks gestation (45 vs. 58% p = 0.033). Women who received preconception counseling were more likely to have stable liver disease at conception (100 vs 86% p = 0.02). Compared with preconception MELD (model for end stage liver disease), preconception Albumin-Bilirubin score (ALBI) more accurately predicted live birth with an area under the receiver-operator curve (AUROC) of 0.741 (p < 0.001), and preconception AST to platelet ratio index (APRI) more accurately predicted ability to proceed beyond 37 weeks gestation with an AUROC of 0.700 (p < 0.001). CONCLUSIONS: Most women with cirrhosis who conceived achieved a successful pregnancy outcome. ALBI and APRI scores can prognosticate pregnancy outcomes in women with CLD. Preconception counseling by a hepatologist or specialist obstetrician improved patient care in this group.Rates of pregnancy in women with cirrhosis are increasing. Risk of hepatic decompensation during pregnancy, therefore, merits tailored obstetric and hepatology care. Prognostic markers that determine pregnancy outcomes are lacking. Medical records of women who attended hepatology clinic at King’s College Hospital with chronic liver disease (CLD) who became pregnant from 1983 to 2017 were reviewed. Information on demographics, clinical history, serology, and outcome of pregnancy was collected. In all, 165 pregnancies occurred in 100 women with CLD including 80 pregnancies in 48 women with cirrhosis. Median age of conception in cirrhotic and non-cirrhotic women were 26 years (16–44) and 28 years (16–51) respectively (p = 0.015). Whilst women with cirrhosis had similar live birth rate to non-cirrhotic women (75 vs. 85% p = 0.119), they were significantly less likely to proceed beyond 37 weeks gestation (45 vs. 58% p = 0.033). Women who received preconception counseling were more likely to have stable liver disease at conception (100 vs 86% p = 0.02). Compared with preconception MELD (model for end stage liver disease), preconception Albumin-Bilirubin score (ALBI) more accurately predicted live birth with an area under the receiver-operator curve (AUROC) of 0.741 (p < 0.001), and preconception AST to platelet ratio index (APRI) more accurately predicted ability to proceed beyond 37 weeks gestation with an AUROC of 0.700 (p < 0.001). Most women with cirrhosis who conceived achieved a successful pregnancy outcome. ALBI and APRI scores can prognosticate pregnancy outcomes in women with CLD. Preconception counseling by a hepatologist or specialist obstetrician improved patient care in this group.


Journal of the American Geriatrics Society | 2018

Efficacy and Tolerability of Direct-Acting Antivirals for Hepatitis C in Older Adults: Direct-acting antivirals in older adults

Chiara Mazzarelli; Aisling Considine; K. Childs; I. Carey; Matteo Angelo Manini; Abid Suddle; Geoffrey Dusheiko; Kosh Agarwal; Mary Cannon

To evaluate the efficacy and tolerability of direct‐acting antiviral (DAA) therapy in individuals aged 65 and older.


Archive | 2002

The Epidemiology of Schizophrenia: Glossary of epidemiological terms

Robin M. Murray; Peter B. Jones; Ezra Susser; Jim van Os; Mary Cannon

Carrier: A person or animal without apparent disease who harbours a specific infectious agent and is capable of transmitting the agent to others. The carrier state may occur in an individual with an infection that is unapparent throughout its course (known as asymptomatic carrier), or during the incubation period, convalescence, and post convalescence of an individual with a clinically recognizable disease. The carrier state may be of short or long duration (transient carrier or chronic carrier).


British Journal of Psychiatry | 1996

Prenatal exposure to the 1957 influenza epidemic and adult schizophrenia : a follow-up study

Mary Cannon; David Cotter; V P Coffey; Pak Sham; Nori Takei; Conall Larkin; Robin M. Murray; Eadbhard O'Callaghan


Archive | 2002

Diagnosis and classification of schizophrenia: categories versus dimensions, distributions versus disease

Jim van Os; Hélène Verdoux; Robin M. Murray; Peter B. Jones; Ezra Susser; Mary Cannon


British Journal of Psychiatry | 1996

Mixed-handedness in patients with functional psychosis.

Rammohan Rao Malesu; Mary Cannon; Peter B. Jones; Kwame McKenzie; K. Gilvarry; Larry Rifkin; Brian Toone; Robin M. Murray


Archive | 2004

Marijuana and Madness: Cannabis as a potential causal factor in schizophrenia

Louise Arseneault; Mary Cannon; John Witton; Robin M. Murray


Archive | 2002

The Epidemiology of Schizophrenia: Childhood development and later schizophrenia: evidence from genetic high-risk and birth cohort studies

Mary Cannon; C. Jane Tarrant; Matti O. Huttunen; Peter Jones


Archive | 2004

Neurodevelopment and Schizophrenia: Early environmental risk factors for schizophrenia

Mary Cannon; Kimberlie Dean; Peter B. Jones

Collaboration


Dive into the Mary Cannon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Kosh Agarwal

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar

K. Childs

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

I. Carey

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jim van Os

Maastricht University Medical Centre

View shared research outputs
Top Co-Authors

Avatar

Kwame McKenzie

Centre for Addiction and Mental Health

View shared research outputs
Top Co-Authors

Avatar

Pak Sham

University of Hong Kong

View shared research outputs
Researchain Logo
Decentralizing Knowledge